Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06607770
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-11
Brief Title:
Safety and Efficacy of Cryoablation With Karelizumab and Apatinib for Multiple Lung Cancers
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Exploratory Study of the Safety and Efficacy of Cryoablation in Combination With Karelizumab and Apatinib for the Treatment of Multiple Primary Lung Cancers Without Known Driver Genes
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to explore the safety and efficacy of cryoablation combined with carlizumab and apatinib in multiple primary lung cancer without known driver genesMain included population criteriaClinical and pathological diagnosis of multiple primary lung cancerThree pulmonary nodules were diagnosed initially or before surgery without lymph node metastasisMale or female is 18 years old and 75 years oldUp to one surgical resection treatment with 2 remaining pulmonary nodules and postoperative pathology confirmed MIA or AIS and so onThe main questions it aims to answer is safety of cryoablation combined with carilizumab and apatinib in multiple primary lung cancerParticipants will take carplus with apatinib started 2-3 weeks after cryoablation Carelizumab 200mg q3w apatinib 250mg qd Every 3 weeks is for one treatment cycle Until PD intolerable toxicity death patient withdrawal or investigator discretion requires termination
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None